Related Experiment Video
Updated: May 31, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria
Tianqiao Zhang1,2,3,4,5, Bo Xu1,2,3,4,5,6, Jixiang Chen1,2,3,4,5,6
1The First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Introduction:
Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disease characterized by hemolytic anemia, bone marrow failure, and thrombosis. Some PNH patients carrying the C5 mutation (Arg885) show poor response to eculizumab and ravulizumab.
Areas Covered:
The US FDA approved PiaSky (crovalimab-akkz) on 20 June 2024, for use in adults or adolescents with PNH. It is a humanized anti-C5 monoclonal antibody, formerly known as SKY59. The main objective of this review is to examine the pharmacological properties of crovalimab and its clinical efficacy and safety.
Expert Opinion:
Crovalimab inhibits the cleavage of complement C5 into C5a and C5b by specifically binding to complement C5, thus preventing terminal complement-mediated intravascular hemolysis in patients with PNH. Based on the pivotal trials COMMODORE 1 and COMMODORE 2, crovalimab had clinical efficacy not inferior to that of eculizumab and exhibited good tolerability and safety, including in controlling hemolysis, avoiding transfusions, and reducing or maintaining lactate dehydrogenase levels. Additionally, crovalimab showed a favorable response in PNH patients carrying C5 variants, and the response in adolescents aged ≥13 years was similar to that in adults. Common adverse events associated with crovalimab include infusion-related reactions, respiratory tract infections, and Type III hypersensitivity reactions.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment Resistent Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
